Literature DB >> 2741189

Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption.

W Kirch1, H D Janisch, E E Ohnhaus, A van Peer.   

Abstract

The pharmacokinetic interaction between the gastrointestinal motility-stimulating substance cisapride and the H2-antagonist cimetidine was examined in 8 healthy volunteers (25 +/- 2 years of age). Steady-state kinetics of both substances were investigated after separate 1-week treatments of oral cisapride, 10 mg t.i.d., cimetidine, 400 mg t.i.d., and the two drugs combined. Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02). Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05). It is concluded that cimetidine inhibits cisapride metabolism, whereas cisapride enhances the gastrointestinal absorption of cimetidine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2741189

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  11 in total

1.  Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation.

Authors:  V H M Deneer; L Lie-A-Huen; J H Kingma; J H Proost; S A Gossen; A Stuurman; G M M Uytdehaag; P H J M Dunselman; J R B J Brouwers
Journal:  Eur J Clin Pharmacol       Date:  2004-11-16       Impact factor: 2.953

2.  Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects.

Authors:  V H Deneer; L Lie-A-Huen; J H Kingma; J H Proost; J C Kelder; J R Brouwers
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 3.  Cisapride. Drug interactions of clinical significance.

Authors:  T A Bedford; D J Rowbotham
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 4.  Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.

Authors:  J M Greiff; D Rowbotham
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

Review 5.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

6.  Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.

Authors:  H Bohets; K Lavrijsen; J Hendrickx; J van Houdt; V van Genechten; P Verboven; W Meuldermans; J Heykants
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 7.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 8.  Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.

Authors:  D A Flockhart; Z Desta; S K Mahal
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

Review 9.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

Review 10.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.